| (Values in U.S. Thousands) | Mar, 2026 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Sep, 2024 |
| Sales | 761,500 | 772,200 | 705,700 | 745,000 | 744,600 |
| Sales Growth | -1.39% | +9.42% | -5.28% | +0.05% | -0.89% |
| Net Income | 88,100 | 47,300 | 64,200 | 68,500 | 85,600 |
| Net Income Growth | +86.26% | -26.32% | -6.28% | -19.98% | +87.72% |
Sartorius Sted Bio (DIM.FP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Euronext FR]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Euronext FR]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
Fiscal Year End Date: 12/31